D.E. Shaw & Co’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

D.E. Shaw & Co’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-408,574	Closed	-$4.13M	–	5150
2022 Q4	$4.13M	Buy	408,574 +150,000	+58%	+$1.5M	﹤0.01%	2275
2022 Q3	$2.56M	Buy	258,574 +400	+0.2%	+$3.95K	﹤0.01%	2767
2022 Q2	$2.52M	Hold	258,174	–	–	﹤0.01%	2860
2022 Q1	$2.52M	Sell	258,174 -135,985	-35%	-$1.32M	﹤0.01%	3085
2021 Q4	$3.82M	Buy	394,159 +165,129	+72%	+$1.61M	﹤0.01%	2682
2021 Q3	$2.21M	Buy	229,030 +195,697	+587%	+$1.89M	﹤0.01%	2946
2021 Q2	$322K	Buy	+33,333	New	+$327K	﹤0.01%	4241

D.E. Shaw & Co's EBAC Position: Q1 2023 in Review

D.E. Shaw & Co sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 408,574 shares — an estimated $4.13M sold.

D.E. Shaw & Co first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $4.13M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

D.E. Shaw & Co reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
D.E. Shaw & Co sold 408,574 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $4.13M.
D.E. Shaw & Co first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
D.E. Shaw & Co's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $4.13M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.